In addition to ibrutinib, people with M-CLL, devoid of TP53 aberrations and suit enough to tolerate FCR therapy, should still be great candidates to the latter, with the reward staying that this treatment could be done in 6 months while ibrutinib needs to be taken indefinitely. This selection can be especially worthwhile for non-compliant individua